Trust & governance
Editorial Standards
How we research, write, source, and correct.
Our editorial standards govern accuracy, sourcing, provider-review rules, originality, updates, correction thresholds, and prohibited claims. Every indexable page must add original information gain, cite primary sources, name its dose concept, and separate provider-reported from verified figures.
Accuracy and sourcing
Claims follow a source hierarchy led by FDA, NIH, ClinicalTrials.gov, state boards, and peer-reviewed literature, then FDA labeling, then first-party provider and pharmacy records. Secondary reporting is context only. Unverified facts are marked pending, not guessed.
Originality
We do not mass-produce articles from reusable generic paragraphs. Independent pages that exceed the permitted similarity threshold or repeat long sections fail our duplicate-content QA and stay unpublished until rewritten.
Prohibited claims
We never publish a universal dosing chart, unit calculator, or titration schedule; never claim a lower dose is safer or equally effective without exact evidence; and never extrapolate approved-injectable trials to compounded oral, sublingual, or ODT products.
Updates and corrections
Pricing refreshes on a 7–14 day target, regulatory monitoring is ongoing, and medical pages are re-reviewed at least annually and after material change. Corrections follow the corrections policy.
Frequently asked questions
How do you prevent duplicate content?
Automated near-duplicate detection compares independent pages; any pair above the similarity threshold, or any repeated long paragraph or medication-name swap, fails QA and blocks publication until the page is genuinely unique.
Publisher: Microdose GLP One. Compounded medications are not FDA approved. Questions or corrections: see the corrections policy and contact page.